Curant Rare Becomes Exclusive Pharmacy Partner for IWILFIN™, Transforming Access and Care for High-Risk Neuroblastoma Patients
Curant Health has announced a major milestone in oncology care through its specialty division, Curant Rare, which is now the exclusive pharmacy partner for IWILFIN™, the first and only FDA-approved oral maintenance therapy proven to reduce the risk of relapse in patients with high-risk neuroblastoma (HRNB). This exclusive partnership officially begins in August 2025, marking a new era in patient-centered care for children and adults living with this aggressive form of cancer.
The collaboration ensures that every patient prescribed IWILFIN™ will transition to Curant Rare’s pharmacy services under the umbrella of the IWILFIN Cares® program. This transition not only guarantees uninterrupted therapy access but also introduces a more advanced, personalized, and digitally enhanced care experience for patients and their families.
Addressing a Critical Need in Neuroblastoma Care
Neuroblastoma is a rare and aggressive cancer that typically affects young children, with high-risk cases posing significant treatment challenges. Despite intensive front-line therapies—including chemotherapy, surgery, stem cell transplants, and immunotherapy—patients with HRNB face a high likelihood of relapse. Studies have shown that IWILFIN™, developed by US WorldMeds, is the only oral therapy that can cut the risk of relapse in half, offering new hope for improved long-term survival.
However, access to such life-saving therapies can often be complicated by fragmented care coordination, insurance hurdles, or delays in treatment delivery. By consolidating all IWILFIN™ distribution under Curant Rare, the partnership aims to solve these challenges by creating a streamlined, supportive, and highly connected care pathway.
Patients First: A Philosophy at the Core
The decision to transition the IWILFIN Cares program to Curant Rare was carefully considered. According to Michelle Stantz, Executive Director of Market Access at US WorldMeds, the driving factor was ensuring that patients remained at the center of every decision.
We’re excited to launch our partnership with Curant Rare, a decision driven by one clear priority—our patients,” said Stantz. “Transitioning the IWILFIN Cares program to a new Specialty Pharmacy Partner was a tough decision, and we needed to find the right partner. Curant Rare is that partner. Together, we are committed to putting patients first—ensuring they receive the support and treatment they need, now and into the future.
This philosophy aligns perfectly with Curant Rare’s mission to deliver compassionate, patient-centered specialty care for rare and complex conditions.
The Enhanced IWILFIN Cares® Experience
The new IWILFIN Cares® program—powered by Curant Rare—goes beyond traditional specialty pharmacy services. It integrates cutting-edge digital tools, personalized support, and comprehensive financial navigation, creating a care ecosystem designed to empower families during every stage of treatment.
1. Seamless Access and Delivery
Patients will continue receiving IWILFIN™ as prescribed without disruption. Curant Rare’s logistics model ensures timely medication delivery with advanced shipment visibility, real-time courier tracking, and proactive reminders. Families will always know when to expect medication, minimizing stress and uncertainty during the treatment journey.
2. Stronger Patient-Caregiver Connections
Each patient and family will be assigned a dedicated Patient Care Coordinator, ensuring continuity and familiarity in their care experience. With smart routing and bi-directional texting, patients can connect directly with the same coordinator every time, fostering trust and building strong, lasting relationships throughout the course of treatment.
3. Digital Engagement and Education
Families will gain access to curated educational resources delivered through digital platforms. These resources are designed to help caregivers better understand neuroblastoma, treatment expectations, potential side effects, and supportive care strategies. Interactive content ensures patients and families feel informed, engaged, and empowered in their healthcare decisions.
4. Insurance and Financial Support
One of the most significant challenges in rare disease treatment is navigating the financial and insurance landscape. Curant Rare’s specialized team will take on full management of insurance approvals, prior authorizations, and financial assistance programs. By exploring every available resource, the program works to reduce financial burdens and minimize out-of-pocket costs for families.
5. A Holistic and Compassionate Approach
By combining personalized communication with advanced technology, the IWILFIN Cares program ensures a comprehensive support system that addresses both the medical and emotional needs of patients and caregivers. This approach underscores Curant Rare’s commitment to not just dispensing medication, but to building an enduring support network for families navigating high-risk neuroblastoma.
Why This Partnership Matters
For families facing a rare and devastating disease like HRNB, every detail of care matters. Missed shipments, delays in insurance approvals, or lack of support during treatment can have profound consequences. By making Curant Rare the exclusive pharmacy partner, US WorldMeds and Curant Health are working together to eliminate these gaps.
The partnership provides three critical benefits:
- Consistency of Care – Every patient now experiences the same high standard of pharmacy support.
- Connected Experience – Enhanced digital tools and communication channels keep families informed and supported in real time.
- Long-Term Commitment – By centering patients and caregivers in the design of IWILFIN Cares, the partnership is focused not just on immediate access but also on longitudinal care across the entire treatment journey.
A New Era in Specialty Pharmacy for Rare Oncology
This collaboration reflects a broader trend in healthcare: specialty pharmacies are evolving from being simple medication dispensers into comprehensive care partners. For rare conditions like HRNB, where treatments are highly specialized and patient populations are small, such tailored approaches are essential.
Curant Rare’s focus on rare and complex diseases positions it as a natural fit for IWILFIN™. By combining clinical expertise, compassionate support, and digital innovation, Curant Rare is redefining how pharmacy partnerships can directly impact outcomes for patients with life-threatening diseases.
